- Home
- MOVE vs PHAT Comparison
MOVE vs PHAT Comparison
Compare MOVE & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MOVE | PHAT |
|---|---|---|
| Founded | 2018 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 901.4M | 894.0M |
| IPO Year | 2021 | 2019 |
Fundamental Metrics
Financial Performance| Metric | MOVE | PHAT |
|---|---|---|
| Price | $19.54 | $11.92 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $19.83 |
| AVG Volume (30 Days) | 52.3K | ★ 1.4M |
| Earning Date | 04-08-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 42.72 |
| EPS | N/A | ★ N/A |
| Revenue | $433,000.00 | ★ $175,110,000.00 |
| Revenue This Year | $1,460.71 | $93.04 |
| Revenue Next Year | $96.77 | $58.91 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 216.93 |
| 52 Week Low | $0.51 | $3.69 |
| 52 Week High | $34.87 | $18.31 |
Technical Indicators
Market Signals| Indicator | MOVE | PHAT |
|---|---|---|
| Relative Strength Index (RSI) | 63.82 | 48.15 |
| Support Level | $6.27 | $10.38 |
| Resistance Level | $20.04 | $12.52 |
| Average True Range (ATR) | 1.82 | 0.98 |
| MACD | 0.51 | -0.01 |
| Stochastic Oscillator | 76.64 | 61.97 |
Price Performance
Historical ComparisonAbout MOVE Movano Inc.
Corvex Inc is an AI cloud computing company specializing in GPU accelerated infrastructure for AI workloads. The company provides AI-focused computing infrastructure that offers scalable computational resources. Its platform uses GPU-accelerated compute clusters and high-throughput storage to support performance, security, and efficiency at scale. The company's product portfolio includes GPU Clusters, Inference-as-a-Service, Confidential Computing, and GPU Node.
About PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.